Massive 3,000-Person check on migraine drug safety
NCT ID NCT06603558
Summary
This study is monitoring the safety and real-world effectiveness of atogepant, an already-approved oral medication for preventing migraines. It will follow 3,000 Korean adults with chronic or episodic migraines who are prescribed the drug by their doctors as part of their normal care. The main goal is to track any side effects and see how well the drug works for preventing migraine attacks over 12 weeks in everyday practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hallym University Dongtan Sacred Heart Hospital /ID# 273581
RECRUITINGHwaseong, Gyeonggido, 18450, South Korea
-
Kangbuk Samsung Hospital /ID# 271893
RECRUITINGSeoul, Seoul Teugbyeolsi, 03181, South Korea
-
Seoul National University Hospital /ID# 271892
RECRUITINGSeoul, Seoul Teugbyeolsi, 03080, South Korea
-
Yonsei University Health System Severance Hospital /ID# 272639
RECRUITINGSeoul, Seoul Teugbyeolsi, 03722, South Korea
Conditions
Explore the condition pages connected to this study.